Media Relations

Our aim is to provide news media with clear, accurate and timely information about our pharmaceutical products, services and business activities.

Media Release

Fighting HER2 + Breast Cancer with innovation and hope

PHESGO – the world's first fixed dose combination of two monoclonal antibodies in Oncology for the treatment of HER-2 positive breast cancer now available in India

Roche's Evrysdi (Risdiplam) - the first and only oral treatment for adults and children two months or older suffering from Spinal Muscular Atrophy (SMA) now available in India.

Roche’s Antibody Cocktail (Casirivimab and Imdevimab) is now available in India, Cipla to market it pan-India

Ronapreve™ (Casirivimab 120mg/ml and Imdevimab 120mg/ml Injection for intravenous infusion or subcutaneous administration) does not retain activity against the Omicron variant.

Roche receives Emergency Use Authorisation in India for its investigational Antibody Cocktail (Casirivimab and Imdevimab) used in the treatment of Covid-19

Company statement on Tocilizumab (Brand: Actemra) supplies

US-FDA Approved Foundation Medicine's foundationone®Liquid cdx, a Pan-Tumor Liquid Biopsy Genomic Test for Late Stage Cancer Patients now Available in India

Roche Pharma India expands partnership with Cipla to further improve access to key oncology medicines

Roche Pharma India partners with Entero Healthcare Solutions to improve access to nephrology medicines

V. Simpson Emmanuel appointed as General Manager, Roche Products (India) Pvt. Ltd.

Roche’s Atezolizumab receives DCGI approval for treatment of metastatic triple-negative breast cancer in India

Roche’s Atezolizumab receives DCGI approval for treatment of extensive-stage small cell lung cancer in India

Roche launches new therapy Emicizumab for people with Hemophilia A on World Hemophilia Day

Roche and St. Jude India ChildCare Centre come together with Dr. B Barooah Cancer Institute to offer holistic cancer care to underprivileged children

Roche Pharma India partners with Cipla to create greater access to key medicines

Media Enquiries

For media enquiries, please contact:
Email: [email protected]